{
    "nctId": "NCT00107263",
    "briefTitle": "Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer",
    "officialTitle": "A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Osteoporosis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 558,
    "primaryOutcomeMeasure": "Average intra-patient change in total lumbar spine (L1-L4) bone mineral density (BMD) as measured by dual energy x-ray absorptiometry at baseline and 1 year after completion of study treatment",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer\n\n  * Stage I, II, or IIIA disease\n* Completed \u2264 6 years of adjuvant tamoxifen therapy\n* Total baseline lumbar spine or femoral neck bone mineral density T-score below -2.0 standard deviation (e.g., a patient with a T-score of -2.1 in ineligible; a patient with a T-score of -1.9 is eligible)\n* No clinical or radiological evidence of recurrent or metastatic disease\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Postmenopausal\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined by 1 of the following:\n\n  * Over 55 years of age with cessation of menses\n  * 55 years of age and under with spontaneous cessation of menses for \\> 1 year\n  * 55 years of age and under with spontaneous cessation of menses for \u2264 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy) with postmenopausal estradiol levels (\\< 5 ng/dL)\n  * Undergone bilateral oophorectomy\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 5 years\n\nHematopoietic\n\n* WBC \u2265 3,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Alkaline phosphatase \u2264 3 times upper limit of normal (ULN)\n* AST \u2264 3 times ULN\n\nRenal\n\n* Creatinine \\< 2.0 mg/dL\n* No hypercalcemia (i.e., calcium \\> 1 mg/dL above ULN within the past 6 months)\n* No hypocalcemia (i.e., calcium \\> 0.5 mg/dL below lower limit of normal within the past 6 months)\n\nOther\n\n* No uncontrolled infection\n* No uncontrolled diabetes mellitus\n* No uncontrolled thyroid dysfunction\n* No disease affecting bone metabolism (e.g., hyperparathyroidism, hypercortisolism, Paget's disease, or osteogenesis imperfecta)\n* No malabsorption syndrome\n* No uncontrolled seizure disorder associated with falls\n* No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or cholecalciferol (vitamin D)\n* No mental illness that would preclude giving informed consent\n* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No other non-malignant systemic disease\n* No clinical or radiologic evidence of existing fracture in the lumbar spine and/or total hip\n* No history of fracture with low intensity or not associated with trauma\n* No contraindication to spinal dual energy x-ray absorptiometry (DEXA) due to any of the following:\n\n  * History of surgery at the lumbosacral spine, with or without implantable devices\n  * Scoliosis with a Cobb angle \\> 15\u00b0 at the lumbar spine\n  * Immobility, hyperostosis, or sclerotic changes at the lumbar spine\n  * Evidence of sufficient sclerotic abdominal aorta that would interfere with DEXA scan\n  * Any disease of the spine that would preclude proper acquisition of a lumbar spine DEXA\n* Considered reliable\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* See Disease Characteristics\n* Prior parathyroid hormone allowed provided it was not administered for \\> 1 week\n* More than 6 months since prior anabolic steroids or growth hormone\n* More than 12 months since prior endocrine therapy (including estrogen) except for the following:\n\n  * Tamoxifen\n  * Insulin\n  * Oral hypoglycemics\n  * Thyroid hormone\n  * Steroid inhalers\n* More than 12 months since prior systemic corticosteroids except short-term corticosteroids to prevent or treat chemotherapy-induced nausea and vomiting or acute respiratory illness\n\n  * Concurrent short-term corticosteroids allowed\n* No other concurrent hormonal therapy\n* No concurrent parathyroid hormone\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* Prior systemic sodium fluoride allowed provided it was not administered for \\> 3 months within the past 2 years\n* More than 3 weeks since prior oral bisphosphonates\n* More than 2 weeks since prior and no concurrent drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate)\n* More than 30 days since prior systemic investigational drugs and/or devices\n* More than 7 days since prior topical investigational drugs\n* No prior IV bisphosphonates\n* No prior aromatase inhibitor therapy\n* No concurrent calcitonin, sodium fluoride, or Tibolone\n* No other concurrent anticancer therapy\n* No other concurrent bisphosphonates\n* No other concurrent investigational drugs or devices",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}